Rafael Carbunaru, PhD, Boston Scientific’s VP of R&D, discusses DBS therapy and STIMVIEW XT, the Company’s new advanced visualization software for DBS programming, in an in-depth interview with SmartTRAK at INS 2022

Rafael Carbunaru, PhD, vice president of research and development for Boston Scientific (BSX), discusses deep brain stimulation (DBS) and STIMVIEW XT, the Company’s new advanced visualization software for DBS programming in an in-depth interview with SmartTRAK at the International Neuromodulation Society (INS) World Congress in Barcelona, Spain held May 21-26.

Used with the Vercise Genus DBS portfolio and developed in collaboration with Brainlab, STIMVIEW XT uses patient-specific 3D visualization of patient anatomy and enables clinicians to see, shape and steer DBS therapy using point-and-click interface designed to simplify programming, save time and better personalize therapy.

To find out more about STIMVIEW XT, DBS workflows and BSX’s vision for DBS, click on the following video to listen to the interview recorded live at INS 2022 (45:16 min). For more details, interview topics by timecode are provided below. A link to download a complete transcript of the interview is also available below.

SmartTRAK reports that challenging conditions lead to minimal innovation in Paris.

It was third time lucky for the approximately 3,500 attendees of the 2022 European Wound Management Association (EWMA) conference in Paris. Although not yet back to a pre-pandemic number of participants, it was encouraging to see an international presence without the barrier of COVID-19 restrictions. Previous dates in 2020 and early 2022 fell to the pandemic, so great credit goes to the organizers and exhibitors for persevering and delivering a positive and engaging event.

Among the many topics covered in this SmartTRAK perspective article, which you can download here, are:

• MDR Consuming R&D Resources
• Clouds over Germany - Is There a Silver Lining?
• Establishing a European Foothold
• The Trend in Using Fewer Layers in Compress

Among the many topics covered in detail in our comprehensive Q122 Spinal Cord Stimulation Market Recap* are:

The return of elective procedure volumes, new product offerings and a busy first quarter of acquisitions all supported healthy growth for the Extremities Market

While growth drivers varied for specific companies in Q122, the return of elective procedure volumes helped drive double-digit growth for several market players. Stryker*, the Extremities Market leader, benefited from the return of elective procedures in the US. Its US Foot & Ankle and Upper Extremities business segments contributed to the Company’s US Trauma & Extremities growth during the quarter. Stryker also noted during its earnings call that ...

Among the many topics covered in detail in our comprehensive Q122 Extremities Market Recap* are:

Ryan Lakin, Abbott DVP of R&D, discusses opportunities in neuromodulation in an interview with SmartTRAK at INS 2022

Surgical matrices procedures appear back to near pre-pandemic levels, with revenues on the rise

With elective procedures in the United States mostly back at pre-pandemic levels, the US Surgical Matrices Market returned to what had been normal growth in Q122, gaining +5.7% YoY according to SmartTRAK Financial Dashboard. AbbVie* continued to lead the Surgical Matrices Market, though it was approximately flat, while Becton Dickinson* (BD) grew strongly.

Among the many topics covered in detail in our comprehensive Q122 US Surgical Matrices Market Recap* are:

WW Advanced Wound Care growth settles to a traditional mid-single digit growth rate as global wound care moves past COVID-19.

SmartTRAK investigates recent trends in hernia repair clinical trials and how these trends relate to competition in the hernia repair market. Using a new SmartTRAK tool to analyze data in clinicaltrials.gov, SmartTRAK describes shifting trends in hernia repair research with company-sponsored studies and randomized controlled trials (RCTs)